Belviq is withdrawn from the market

Almost at the end of the year 2014, the FDA announced approval of Novo nordisk's Saxenda(liraglutide), a powerful new injectable weight loss drug in addition to diet and exercise to fight the obesity epidemic. Saxenda has the same active ingredient as the diabetes medication Victoza although at a higher dosage of 3.0 mg instead of 1.2 mg or 1.8 mg in Victoza. Saxenda is the 2 nd weight loss drug to be approved in 2014 by the US FDA after Takeida pharmaceuticals Contrave was approved a few months prior and fourth weight loss drug to be approved since June of 2012 when Arena Pharmaceuticals Belviq and Orexigen's Qsymia were approved. 1. What do you need to know about Saxenda for weight loss? Saxenda® (liraglutide 3 mg) is new class of medications to be considered for weight loss - a class of drugs known as incretins. Containing glucagon-like peptide-1 (GLP-1) analogue with 97% similarity to naturally occurring human GLP-1, incretins contain an anologue similar